News
FDA Warning Letters List Typical Pharma Regulatory Issues
According to a study of the reasons behind warning letters sent by the US Food and Drug Administration Center for Drug Evaluation and Research and Center for Devices and Radiological Health between 2010 and 2020, poor current good manufacturing practise (cGMP) compliance and...
News
CRISIL Predicts Indian Pharma Sales To Rise 7%-9% In FY23
Due to challenges in export sales in the regulated markets and a large base effect in the home formulations sector, the Indian pharmaceutical industry is anticipated to achieve moderate revenue growth of 7-9% in the current fiscal.
Because of ongoing...
Drug Research
NHS To Deploy Variant-Busting Booster Jab Ahead of Winter
The NHS has now laid out plans for the next stage of the COVID-19 vaccination effort, the biggest and most rapid vaccine drive in the history of the health service, in response to the updated guidelines outlined by the...
Drug Research
Priority Review of Lynparza If Paired With Abiraterone In US
Priority consideration has been given to AstraZeneca's supplemental new drug application for Lynparza (olaparib) when used in conjunction with abiraterone, prednisone, or prednisolone to treat elderly patients with advanced castration-resistant prostate cancer (mCRPC).
AstraZeneca and MSD, also known as Merck...
News
Healthcare Benefits of Using Turmeric
It’s not surprising that turmeric has become one of the most common pantry staples and popular supplements. After all, not only does the spice add an incredible flavor to specific dishes, but it also possesses properties that can potentially...
Drug Research
Trends of Genuv Cancer Drug Show Potential For Alzheimers
Mekinist (trametinib), which has been licenced by the FDA for the treatment of melanoma, was shown in a preclinical trial to have a neuroprotective impact on Alzheimer's disease, according to Genuv Inc. of South Korea, which has announced the...
Drug Research
Axsome Pitches Auvelity As A Depression Med Game-Changer
It is commonly known that there are insufficient therapy choices for major depressive disorder. Then the pandemic struck, increasing the number of patients with MDD diagnoses and the unmet demand.
In light of this, the time is right for the...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read